The reliance on molecular pathology tests underpins the future of “Personalised Medicine”, a disease management paradigm where treatment decisions are increasingly informed by biological characteristics. THD funding will be used to increase molecular pathology capability across Australia including the development of a national reference laboratory for cancer-related molecular pathology, a collaboration between the Peter MacCallum Cancer Centre, the Department of Pathology at The University of Melbourne and other Victorian Comprehensive Cancer Care Centre partners.
THD funding will also be used for infrastructure enabling increased participation in cutting edge clinical research involving biomarker assessment, leveraging significant research programs at the Garvan Institute, SA Pathology (Centre of Cancer Biology) and the University of Queensland Centre for Clinical Research (UQCCR).
The new Facilities are now part of a continuum that spans the two pillars of personalised medicine: fast and accurate diagnostic testing, and accelerated drug screening. THD funding will assist in increasing capacity to develop and perform new molecular tests, increase existing molecular diagnostic capacity and reducing the cost of tests.